- Home
- Z vs BMRN Comparison
Z vs BMRN Comparison
Compare Z & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- Z
- BMRN
- Stock Information
- Founded
- Z 2004
- BMRN 1996
- Country
- Z United States
- BMRN United States
- Employees
- Z N/A
- BMRN N/A
- Industry
- Z Business Services
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- Z Consumer Discretionary
- BMRN Health Care
- Exchange
- Z Nasdaq
- BMRN Nasdaq
- Market Cap
- Z 17.0B
- BMRN 13.7B
- IPO Year
- Z 2011
- BMRN 1999
- Fundamental
- Price
- Z $66.46
- BMRN $69.36
- Analyst Decision
- Z Buy
- BMRN Buy
- Analyst Count
- Z 26
- BMRN 22
- Target Price
- Z $81.64
- BMRN $94.00
- AVG Volume (30 Days)
- Z 2.9M
- BMRN 1.5M
- Earning Date
- Z 04-30-2025
- BMRN 04-23-2025
- Dividend Yield
- Z N/A
- BMRN N/A
- EPS Growth
- Z N/A
- BMRN 153.71
- EPS
- Z N/A
- BMRN 2.21
- Revenue
- Z $2,236,000,000.00
- BMRN $2,853,915,000.00
- Revenue This Year
- Z $16.41
- BMRN $12.23
- Revenue Next Year
- Z $14.79
- BMRN $9.90
- P/E Ratio
- Z N/A
- BMRN $32.37
- Revenue Growth
- Z 14.96
- BMRN 17.97
- 52 Week Low
- Z $38.45
- BMRN $60.63
- 52 Week High
- Z $89.39
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- Z 38.25
- BMRN 46.15
- Support Level
- Z $69.50
- BMRN $69.60
- Resistance Level
- Z $74.49
- BMRN $73.18
- Average True Range (ATR)
- Z 2.54
- BMRN 1.63
- MACD
- Z 0.11
- BMRN -0.32
- Stochastic Oscillator
- Z 8.00
- BMRN 19.75
About Z Zillow Group Inc. Class C Capital Stock
Zillow Group Inc is an Internet-based real estate company that offers its customers an on-demand experience for selling, buying, renting, or financing with transparency and ease The group works with real estate agents, brokers, builders, property managers, and landlords to pair technology with top-notch service. The group has brands such as Zillow, Trulia, StreetEasy, Hotpads, Zillow Rentals, Zillow Home Loans, ShowingTime, Follow Up Boss, Aryeo and others.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.